Products

Biotinylated Human HLA-A*02:01&B2M&MAGE-A2 Monomer

Overview Specification

Product Name	Biotinylated Human HLA-A*02:01&B2M&MAGE-A2 Monomer
Cat. No.	MHCRP-0359
Category	Proteins & Peptides
Product Description	Recombinant Biotinylated Human HLA-A02:01&B2M&MAGE-A2 (KMVELVHFL) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-terminus. It contains Gly25-Thr305 (HLA-A02:01), Ile21-Met119 (B2M) and KMVELVHFL peptide.
Size	100/500 μg
Format	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Storage	Store at -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Shipping Temp	Shipped at ambient temperature.
Lead Time	Product delivery time depends on the supplier.
Species	Human
Expression Host	HEK293
Accession No	A0A140T913(HLA-A*02:01)&P61769(B2M)&KMVELVHFL
Tag	C-His-Avi
Tag Position	C-terminus
Molecular Type	Monomer
Molecular Weight (MV)	The protein has a predicted MW of 50.50 kDa. Due to glycosylation, the protein migrates to 52-62 kDa based on Bis-Tris PAGE result.
Gene Synonyms	MAGE-A2; MAGEA2
Endotoxin Residue	Less than 1 EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE; > 95% as determined by HPLC.
Amino Acid Range	Gly25-Thr305 (HLA-A*02:01), Ile21-Met119 (B2M), and KMVELVHFL peptide
Product Background	Melanoma antigen gene (MAGE)-A2 (MAGEA2) is a member of the MAGE-A family proteins widely studied for cancer vaccine development and identification of tumor markers. MAGEA2 plays an oncogenic role in glioma progression, and they provide insight into MAGEA2 application as a novel predictor of clinical outcomes and a potential glioma biomarker.
Allele	HLA-A*02:01
Biotinylated	Yes

For research or industrial raw materials, not for personal medical use!